Debra Richardson to Neoplasm Recurrence, Local
This is a "connection" page, showing publications Debra Richardson has written about Neoplasm Recurrence, Local.
Connection Strength
3.549
-
Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity. Am J Clin Oncol. 2018 08; 41(8):797-801.
Score: 0.515
-
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):196-202.
Score: 0.498
-
Isolated groin recurrence of vulvar cancer salvaged with multimodality therapy. Gynecol Oncol. 2009 Nov; 115(2):306-7.
Score: 0.275
-
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2008 Dec; 111(3):461-6.
Score: 0.261
-
Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer. Gynecol Oncol. 2008 Feb; 108(2):449-51.
Score: 0.246
-
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug 05; 34(8):1283-1289.
Score: 0.195
-
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol. 2024 06; 185:202-211.
Score: 0.193
-
Is there a role for secondary debulking in ovarian cancer? A review of the current literature. Curr Opin Obstet Gynecol. 2023 02 01; 35(1):1-5.
Score: 0.172
-
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022 07; 166(1):44-49.
Score: 0.167
-
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 04; 161(1):113-121.
Score: 0.153
-
Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer. Am J Clin Oncol. 2018 10; 41(10):933-937.
Score: 0.130
-
Paclitaxel and Pazopanib in Ovarian Cancer-Reply. JAMA Oncol. 2018 09 01; 4(9):1299.
Score: 0.130
-
Locally Advanced Cervical Cancer: Outcomes With Variable Adherence to Treatment. Am J Clin Oncol. 2018 05; 41(5):447-451.
Score: 0.127
-
Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):477-483.
Score: 0.120
-
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? Int J Gynecol Cancer. 2013 Jun; 23(5):833-8.
Score: 0.090
-
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol. 2011 May 01; 121(2):269-72.
Score: 0.077
-
Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy? Int J Gynecol Cancer. 2010 Oct; 20(7):1125-31.
Score: 0.075
-
Advances in antibody-drug conjugates for gynecologic malignancies. Curr Opin Obstet Gynecol. 2023 02 01; 35(1):6-14.
Score: 0.044
-
Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion. Int J Gynecol Cancer. 2020 11; 30(11):1738-1747.
Score: 0.037
-
Factors influencing primary treatment of midline vulvar cancers. Gynecol Oncol. 2016 07; 142(1):133-138.
Score: 0.028
-
Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer. Obstet Gynecol. 2009 Jan; 113(1):11-17.
Score: 0.017